Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~For Patient:~* Older than 2 years of age and between 6 and 136 kg body weight~* Recipient of clinical diagnosis of epilepsy, taking a stable antiepileptic drug regimen for at least 2 weeks, and requiring intermittent medical intervention to control episodes of acute repetitive seizures (ARS)~* Experienced at least 2 episodes of ARS in previous year, one of which occurred in previous 6 months~* Has episodes of ARS that include complex partial or generalized seizures~* Has a responsible caregiver available to participate~* Is not pregnant or lactating and is practicing an acceptable method of birth control.~For Caregiver:~* Age of 18 years or older and has demonstrated responsibility as a caregiver through training to:~  * Recognize an episode of repetitive seizures for which the injection was intended,~ * Administer study drug~ * Count and record seizures and respiratory rate in the patient diary,~ * Monitor the patient and record observations in the patient diary for 12 hours following study drug treatment~ * Recognize the need for immediate medical attention.~Key Exclusion Criteria~For Patient:~* Petit mal status or petit mal variant status~* History of ARS consistently progressing to status epilepticus~* History of failure to respond to benzodiazepine treatment~* Hypersensitivity to diazepam~* Acute narrow angle glaucoma~* Alcohol and/or other substance abuse~* Has taken another investigational drug in previous 30 days~* Acute or progressive neurologic or severe psychiatric disease or severe mental abnormality.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): During the Double-blind Period, participants received a single, age- and weight-appropriate dose of placebo solution as a deep intramuscular injection in the mid to outer thigh. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of acute repetitive seizures (ARS).
- Diazepam (Type: EXPERIMENTAL): During the Double-blind Period, participants received a single, age- and weight-appropriate dose of diazepam solution, ranging from 0.2 to 0.5 mg/kg, as a deep intramuscular injection in the mid to outer thigh. Additional doses were permissible during the Open-label Period. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of ARS.

Based on this trial design, predict the completion outcome and termination type (if applicable).